Miller, Diane M. (CDC/NIOSH/EID)

From: Doug.Anderson@NeutronicsInc.com
Sent: Thursday, August 21, 2008 11:54 PM
To: NIOSH Docket Office (CDC)
Cc: Chen, Jihong (Jane) (CDC/NIOSH/EID) (CTR); Doyle, Glenn (CDC/NIOSH/EID)
Subject: 039-A - Subpart-Q-CC-SCBA-Concept Comments

Name
Doug Anderson

Organization
Biomarine Inc.

Email
Doug.Anderson@NeutronicsInc.com

Address
456 Creamery Way
Exton, PA 19341
USA

Comments
As a manufacturer I would like to again convey Biomarine's acceptance of subsection Q. This is long overdue and will aid manufacturers in the controlling of costs to the end users. With the enactment of subsection Q it is perceived that we will no longer be required to have diffient models for EN145 and NIOSH certifiction. This will reduce management, engineering and sales costs and ultimately place our end users into a situation where a BioPak 240R in the USA is the same as a BioPak 240R any else in the world. While this may not seem to a big deal to normal USA users it will be a great advantage to users in Canada who adhere to both NIOSH and EN145 standards.